Excessive β-Blockade With Timolol Eye Drops

JAMA: The Journal of the American Medical Association

Volumn 275, Issue 13, 1996, Pages 985-

  Novack, Gary D ^a  

^a Pharma Logic Development Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EYE DROPS; TIMOLOL;

HUMAN; INHALATIONAL DRUG ADMINISTRATION; NOTE; PHARMACOGENETICS; BETA ADRENERGIC RECEPTOR BLOCKING; DRUG ABSORPTION; DRUG FORMULATION; DRUG METABOLISM; INTRANASAL DRUG ADMINISTRATION; LETTER; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-ANTAGONISTS; HUMANS; OPHTHALMIC SOLUTIONS; PHARMACOGENETICS; TIMOLOL; ADMINISTRATION, INTRANASAL;

EID: 0039609889     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1996.03530370023015     Document Type: Letter

References (6)

1. Edeki TI, He H, Wood AJJ. Pharmacogenetic explanation for excessive β-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction. JAMA. 1995;274:1611-1613.
2. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol. 1984;102:551-553.
3. Passo MS, Palmer EA, van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91:1361-1363.
4. Atkins JM, Pugh BR, Timewell RM. Cardiovascular effects of topical beta-blockers during exercise. Am J Ophthalmol. 1985;99:173-175.
5. Charap AD, Shin DH, Petursson U, et al. The effect of varying drop size on the efficacy and safety of a topical beta-blocker. Ann Ophthalmol. 1988;21:351-357.
6. Novack GD. Ophthalmic beta-blockers since timolol. Surv Ophthalmol. 1987; 31:307-327.